WAPPS will take care of predicting the concentration at the time of the measurement you provide, based on the PK profile you intend to validate, using the appropriate dose and patient covariates.
We have been receiving questions regarding Afstyla and whether WAPPS-Hemo already multiplies the resultant measurements by a factor of 2 if a one-stage clotting assay was used. Conversely, the scientific community recommends the use of chromogenic assays or to “calibrate” the clotting assays with a specific standard.
We are excited to announce that as of today, myWAPPS, a patient tool based on WAPPS-Hemo, is globally available from the App store and Google Play.
Due to the different labelled potencies of Xyntha and ReFacto AF (1 IU: 1.38 IU), please ensure that you have selected the correct concentrate that your patient has infused with (Xyntha vs. ReFacto AF). WAPPS-Hemo will take into account potency conversion and you do not need to make any adjustments to your measurements.
With the recent availability for WAPPS-Hemo to process Rebinyn/Refixia requests, we recognize that there are recommendations to use certain lab test assays over others. Based on studies by Bowyer et al 2016, ABC et al 2015, … we recommend that FIX:C in Rebinyn/Refixia-containing plasma samples can be most accurately measured with one-stage clotting assays using SynthAFax or DG Synth [to be internally verified], whereas there is no preference with chromogenic assays.
At WAPPS-News we post the latest updates and changes to the WAPPS-Hemo program. Check back with us regularly. Contact us if you have any questions.
The WAPPS-HEMO Team
If you have any WAPPS-Hemo related research or news items you would like to share, please contact us
© 2025 Copyright WAPPS-Hemo
